The
pharma company announced a breakthrough in their research for a new cancer treatment.
制药公司宣布在新型癌症治疗方法的研究中取得了突破。
The
pharma industry is under increased scrutiny due to rising drug prices.
由于药品价格的上涨，制药行业受到了更严格的审查。
Our
pharma client is seeking regulatory approval for a novel vaccine.
我们的制药客户正在寻求一种新疫苗的监管批准。
The
pharma conference brought together experts from around the world to discuss the latest advancements in drug discovery.
制药会议汇集了全球专家，共同讨论药物发现的最新进展。
The government has allocated funds to support
pharma startups working on innovative therapies.
政府已拨款支持致力于创新疗法的制药初创企业。
The
pharma giant announced plans to expand its R&D facilities to accelerate drug development.
这家制药巨头宣布了扩大其研发设施的计划，以加速药物开发。
The collaboration between the tech firm and the
pharma company aims to leverage AI in drug trials.
科技公司与制药公司的合作旨在利用人工智能进行药物试验。
The
pharma sector faces challenges in balancing affordability with the high costs of research and development.
制药业面临着平衡研究与开发高成本与药品可负担性之间的挑战。
The clinical trial results published by the
pharma firm showed promising efficacy for their new antiviral drug.
制药公司公布的临床试验结果显示，他们的新型抗病毒药物具有良好的疗效。
Investors are keeping a close eye on the
pharma market, expecting growth in biologics and personalized medicine.
投资者密切关注制药市场，预计生物制剂和个性化医疗将出现增长。
Multinational pharma company Novartis said that it would join hands with a PNH patient organization.
跨国制药公司诺华表示，将与PNH患者组织携手合作。
Bian Xin, CEO of Roche Pharma China, said China has taken a lead in developing digital economy, with Chinese people quite open to a digital lifestyle, and the company therefore believes digital-empowered personalized healthcare solutions will be the answer for enhancing the life quality for patients in China.
罗氏制药中国区首席执行官边欣表示，中国在发展数字经济方面处于领先地位，中国人对数字生活方式持开放态度，因此该公司相信，数字化的个性化医疗解决方案将是提高中国患者生活质量的答案。
Li Bin, vice-president of Medical Affairs and Personalized Healthcare (PHC) at Roche Pharma China, said the company hopes to provide not only innovative medicines and diagnostic products, but also aims to develop digital tools and services for personalized healthcare.
罗氏制药中国区医疗事务和个性化医疗副总裁李斌表示，该公司不仅希望提供创新药物和诊断产品，还希望开发个性化医疗的数字工具和服务。
"The vision of the ILD ecosystem is to create one-stop solutions covering disease education, early screening, diagnosis, precision treatment, and management of the diseases," said Chen Xingrong, general manager of human pharma of Boehringer Ingelheim Great China.
勃林格殷格翰大中华区人类制药总经理陈兴荣表示：“ILD生态系统的愿景是创建涵盖疾病教育、早期筛查、诊断、精准治疗和疾病管理的一站式解决方案。”。
Chinese pharmaceutical company Fosun Pharma and its overseas member companies and global partners are participating in the China International Import Expo for the sixth consecutive time this year.
中国医药公司复星医药及其海外成员公司和全球合作伙伴今年连续第六次参加中国国际进口博览会。
This year, Fosun Pharma's booth is showcasing its latest innovations achievements.
今年，复星医药的展台将展示其最新的创新成果。
Furthermore, AbbVie is spearheading a healthcare innovation ecosystem that engages the government, pharma, researchers and industry associations to discover innovative medicines and solutions that address complex health issues and deliver on the commitment to patient centricity.
此外，AbbVie正在引领一个医疗保健创新生态系统，让政府、制药、研究人员和行业协会参与进来，发现解决复杂健康问题的创新药物和解决方案，并履行以患者为中心的承诺。
Other pillars for the company, which has a complete portfolio covering prevention to treatment and will preside over the CIIE Pharma Committee this year, include improving accessibility and affordability for patients and consumers, sustaining long-term partnerships with customers and strengthening capabilities in data analysis, digitalization, and lifecycle management of products at different stages so they have greater value for patients, Van Acker said.
该公司的其他支柱包括提高患者和消费者的可及性和可负担性，与客户保持长期合作伙伴关系，以及加强数据分析、数字化、，以及不同阶段产品的生命周期管理，因此它们对患者有更大的价值，Van Acker说。
Safety valve maker eyes expansion in food, pharma sectors amid soaring demandUpbeat about the Chinese market, LESER GmbH & Co KG, a German safety valve manufacturer, will further expand its market share in the country's food and pharmaceutical industries to maintain robust growth in the years ahead, said a senior executive.
一位高管表示，在需求飙升的情况下，安全阀制造商着眼于在食品和制药领域的扩张。德国安全阀制造商LESER GmbH&Co KG将进一步扩大其在中国食品和制药行业的市场份额，以在未来几年保持强劲增长。
German biopharmaceutical company Boehringer Ingelheim announced on Sept 22 that it will present eight new products and solutions related to human pharma and animal health for the first time at the sixth China International Import Expo (CIIE) in Shanghai this November.
德国生物制药公司勃林格殷格翰9月22日宣布，将在今年11月于上海举行的第六届中国国际进口博览会上首次展示8种与人类药物和动物健康相关的新产品和解决方案。
"In the field of human pharma, the company will present innovative products for rare skin diseases, obesity, pulmonary fibrosis, mental health, and cancer at the CIIE.
“在人类制药领域，该公司将在进博会上展示针对罕见皮肤病、肥胖、肺纤维化、精神健康和癌症的创新产品。
The company said it is aiming to have more than 30 new medical approvals in human pharma by 2029.
该公司表示，其目标是到2029年在人类制药领域获得30多项新的医疗批准。
Cytiva's 2023 Global Biopharma Resilience Index, a survey of 1,250 biopharma and pharma executives in 22 countries, showed that 59 percent of respondents in China believe the country is somewhat adapted to supporting the rollout of personalized medicines and cell and gene therapies.
Cytiva的2023年全球生物制药弹性指数对22个国家的1250名生物制药和制药高管进行了调查，结果显示，59%的中国受访者认为中国在一定程度上适应了支持个性化药物以及细胞和基因疗法的推出。
Under the partnership, IFC, a member of the World Bank Group and the largest global development institution focusing on the private sector of emerging markets, will provide subsidiaries of Fosun Pharma with loans totaling 50 million euros ($53.58 million) to support the construction of a manufacturing site near Abidjan, Cote d'Ivoire, that will produce anti-malaria drugs and antibacterial medicines.
根据该合作伙伴关系，国际金融公司是世界银行集团的成员，也是专注于新兴市场私营部门的最大全球发展机构，将向复星医药的子公司提供总额为5000万欧元（5358万美元）的贷款，以支持在科特迪瓦阿比让附近建造一个制造基地，这将生产抗疟疾药物和抗菌药物。
The project will improve access to quality, affordable life-saving medicines across West Africa, contributing to better health outcomes in a region that contends with heavy loads of infectious and other diseases, Fosun Pharma said.
复星医药表示，该项目将改善西非各地获得优质、负担得起的救命药物的机会，有助于改善该地区的健康状况，该地区正与大量传染病和其他疾病作斗争。
"We're glad to be supported by IFC to localize pharmaceutical manufacturing and distribution in Africa," said Wu Yifang, chairman of Fosun Pharma.
复星医药董事长吴贻芳表示：“我们很高兴得到国际金融公司的支持，在非洲实现药品生产和分销本地化。”。
Since 2006, IFC has repeatedly provided financial and advisory support to Fosun Pharma, which is committed to ensuring the accessibility and affordability of pharmaceutical products and improving the healthcare supply chain resilience in the region, he said.
他说，自2006年以来，国际金融公司多次向复星医药提供财务和咨询支持，复星医药致力于确保药品的可及性和可负担性，并提高该地区的医疗保健供应链弹性。
As the first Chinese drug brand widely recognized in Africa, Artesun (Artesunate for Injection), independently developed and manufactured by Fosun Pharma, has treated over 56 million patients with severe malaria worldwide.
作为第一个在非洲获得广泛认可的中国药品品牌，复星医药自主研发生产的Artesun（注射用青蒿琥酯）已在全球治疗了5600多万名重症疟疾患者。
Chinese pharmaceutical company Luye Pharma Group Ltd sold its medical products like central nervous system medicine to emerging markets in Latin America, Africa and Eastern Europe.
中国制药公司鹿野制药集团有限公司向拉丁美洲、非洲和东欧的新兴市场销售中枢神经系统药物等医疗产品。
Clariant plans to develop two halogen-free flame retardants production facilities in Daya Bay in Guangdong province with one to be put into operation this year with a total investment of $100 million, together with a new $80 million investment in chemicals for personal and home care, industrial applications and pharma industries.
科莱恩计划在广东省大亚湾开发两个无卤阻燃剂生产设施，其中一个将于今年投入运营，总投资为1亿美元，另外还将投资8000万美元用于个人和家庭护理、工业应用和制药行业的化学品。
BI China also saw its human pharma production and supply site in Zhangjiang, Shanghai become the first carbon neutral pharmaceutical plant certified by both Guangzhou Emission Exchange and TUV Rheinland last year.
去年，BI中国还在上海张江的人类制药生产和供应基地成为第一家获得广州排放交易所和莱茵TUV认证的碳中和的制药厂。
The US Food and Drug Administration announced earlier this week that it had approved a medicine from Luye Pharma Group for the treatment of schizophrenia in adults and as monotherapy or adjunctive therapy for the maintenance treatment of bipolar I disorder in adults.
美国食品和药物管理局本周早些时候宣布，已批准鹿野制药集团的一种药物用于治疗成人精神分裂症，并作为成人双相情感障碍维持治疗的单一疗法或辅助疗法。
The medicine was developed by Luye Pharma on its own microsphere technology platform.
该药物由鹿野制药在自己的微球技术平台上开发。
During the event, participants from the CIIE Bureau and members of the CIIE Public Health Epidemic Prevention Special Committee discussed how foreign pharma companies could coordinate resources and collaborate so as to empower China's public health system.
活动期间，来自中国出入境检验检疫局的与会者和中国出入境检测检疫局公共卫生防疫特别委员会的成员讨论了外国制药公司如何协调资源和合作，以增强中国公共卫生系统的能力。
Fosun Pharma will have its portfolio companies and business partners showcase their latest innovations at the upcoming 5th China International Import Expo, the China-based global healthcare group announced during a recent media briefing.
总部位于中国的全球医疗集团复星医药在最近的一次媒体吹风会上宣布，复星医药将在即将到来的第五届中国国际进口博览会上，让其投资组合公司和业务合作伙伴展示他们的最新创新。
They include the world's first oral targeted drug for psoriasis Otezla, the third-generation COMT inhibitor Ongentys to treat Parkinson's disease, and a home beauty instrument, LMNT one, which was developed with Israel's energy source technology, according to Yi Jinyuan, general manager of public relations at Fosun Pharma.
复星医药公共关系总经理易金元表示，其中包括世界上第一种治疗银屑病的口服靶向药物Otezla，治疗帕金森病的第三代COMT抑制剂Ongentys，以及使用以色列能源技术开发的家用美容仪LMNT one。
In addition, Fosun International and Fosun Pharma will host the 5th Hongqiao International Health Technology Innovation Forum on the morning of Nov 6 at Primus Hotel Hongqiao, Shanghai.
此外，复星国际和复星医药将于11月6日上午在上海虹桥普瑞慕斯酒店举办第五届虹桥国际健康科技创新论坛。
"CIIE has played a pivotal role in helping Fosun Pharma become a world-leading pharmaceutical and healthcare enterprise," said Wen Deyong, CEO of Fosun Pharma.
复星医药首席执行官温德勇表示：“CIIE在帮助复星医药成为世界领先的制药和医疗保健企业方面发挥了关键作用。”。
Over the past four years, several innovative products that Fosun Pharma had exhibited at the CIIE - they include cutting-edge medical devices like the da Vinci Surgical robot, a magnetic resonance guided radiation therapy system, and the CAR-T cell therapy - have gone on to enter the Chinese market.
在过去的四年里，复星医药在进博会上展出的几款创新产品——包括达芬奇手术机器人、磁共振引导放射治疗系统和CAR-T细胞疗法等尖端医疗设备——已经进入中国市场。
Wen pointed out that some of Fosun Pharma's global partners have even been convinced to deepen their roots in China and increase investments after attending the annual expo.
温指出，复星医药的一些全球合作伙伴在参加完一年一度的博览会后，甚至被说服要在中国扎根并增加投资。
For example, in August 2022, Intuitive Fosun, a joint venture by Intuitive Surgical and Fosun Pharma, started building its manufacturing and R&D center for medical robots in Pudong New Area, Shanghai.
例如，2022年8月，Intuitive Surgical和复星医药的合资企业Intuitive Fosun开始在上海浦东新区建设其医疗机器人制造和研发中心。
BeiGene said it is working with NewBridge Pharmaceuticals, a local specialty company that has partnerships with global pharma and biotech companies, to bring the drug to patients in Kuwait, Bahrain, Qatar, Saudi Arabia, United Arab Emirates and other markets in the Middle East and North Africa region following regulatory approval.
百济基因表示，在监管部门批准后，它正在与当地的一家与全球制药和生物技术公司有合作关系的专业公司NewBridge Pharmaceuticals合作，将该药物带给科威特、巴林、卡塔尔、沙特阿拉伯、阿拉伯联合酋长国以及中东和北非地区其他市场的患者。
"We hope to enhance cooperation with clinical research centers in Shanghai and see the acceleration of the enrollment and research process of new drug clinical trial projects of local innovative pharma companies.
“我们希望加强与上海临床研究中心的合作，并看到当地创新制药公司新药临床试验项目的注册和研究进程加快。
Through this collaboration, Roche Pharma China will further enrich the hematology portfolio, expand the panorama of lymphoma treatment and continue to work together to promote the standardization of lymphoma treatment in China.
通过此次合作，罗氏制药中国公司将进一步丰富血液学产品组合，扩大淋巴瘤治疗的全景，并继续共同努力，促进中国淋巴瘤治疗的标准化。
"Roche is exploring a business model that focuses on the therapeutic areas of disease while working with partners to address the pain points of the overall treatment journey of patients," said Vivian Bian, CEO of Roche Pharma China.
“罗氏正在探索一种专注于疾病治疗领域的商业模式，同时与合作伙伴合作，解决患者整体治疗过程中的痛点，”罗氏制药中国首席执行官Vivian Bian说。
Everest Medicines, a Hong Kong-listed Chinese biopharmaceutical company, announced on Thursday that it has entered into a memorandum of understanding for a partnership with China Resources Pharmaceutical Group Ltd, or CR Pharma, with the intent to establish an independent company focused on the discovery, development, and commercialization of messenger RNA vaccines.
周四，在香港上市的中国生物制药公司Everest Medicines宣布，已与华润医药集团有限公司（CR Pharma）签署合作谅解备忘录，旨在成立一家独立公司，专注于信使RNA疫苗的发现、开发和商业化。
Through this proposed partnership with CR Pharma, the mRNA-focused company will be well-positioned to advance its potentially best-in-class mRNA vaccine candidates through Chinese regulatory pathways and into commercialization, Everest said.
Everest表示，通过与CR Pharma的拟议合作，这家专注于信使核糖核酸的公司将处于有利地位，能够通过中国的监管途径推进其潜在的同类最佳信使核糖核酸候选疫苗并实现商业化。
CR Pharma, a subsidiary of State-owned China Resources (Holdings) Co Ltd, said through this cooperation, the two companies intend to work together in the development of mRNA COVID-19 vaccine and the development of other potential products using the mRNA technology platform, to contribute to China's public health.
国有华润（控股）有限公司的子公司华润医药表示，通过此次合作，两家公司打算共同开发mRNA新冠肺炎疫苗，并利用mRNA技术平台开发其他潜在产品，为中国的公共健康做出贡献。
According to the annual result report, Human Pharma was still the main revenue contributor, helping the company retain a leading position among multinational pharma companies in China.
根据年度业绩报告，Human Pharma仍然是主要的收入贡献者，帮助该公司在中国跨国制药公司中保持领先地位。
"Reed, formerly the head of Roche Pharma Research and Early Development (pRED), joined Sanofi in 2018, where he participated in and witnessed a crucial strategic transformation of the company.
“Reed，前罗氏制药研究与早期开发部（pRED）负责人，于2018年加入赛诺菲，参与并见证了公司的关键战略转型。
"Wu Yifang, chairman and CEO of Fosun Pharma, said Fosun Pharma always regards innovation as a core driving force for development.
”复星医药董事长兼CEO吴贻芳表示，复星医药始终把创新作为发展的核心动力。
Given its global footprint, Fosun Pharma can help address unmet clinical needs and improve the accessibility and affordability of COVID-19 treatments in low- and middle-income countries worldwide.
鉴于其全球足迹，复星医药可以帮助解决全球中低收入国家未满足的临床需求，并提高新冠肺炎治疗的可及性和可负担性。
The Zhangjiang Biotech and Pharmaceutical Industrial Base, dubbed "Zhangjiang Pharma Valley", is one of the top biotech hubs in China and is home to over 1,000 innovative biotechnology and biopharmaceutical companies.
张江生物医药产业基地被称为“张江制药谷”，是中国顶尖的生物技术中心之一，拥有1000多家创新生物技术和生物制药公司。
Since then, together with our local partners in the GBA, we are exploring possibilities in pharma innovation, promote the future development of pharmaceutical retail, and strengthen the healthcare innovation ecosystem in the region, in turn continuously bringing high-quality innovative drugs to more Chinese patients.
从那时起，我们与GBA的当地合作伙伴一起，探索制药创新的可能性，促进制药零售的未来发展，并加强该地区的医疗保健创新生态系统，从而不断为更多的中国患者带来高质量的创新药物。
Other multinational companies working with local partners to build an open, cooperative, and innovative local health ecosystem include Roche Pharma and Roche Dia, which joined hands for the fourth straight year at CIIE.
其他与当地合作伙伴合作建立开放、合作和创新的当地健康生态系统的跨国公司包括Roche Pharma和Roche Dia，它们连续第四年在CIIE携手合作。
According to the report, China's pharma innovation ecosystem has taken shape in the past five years, and one of the top priorities in the ecosystem now is accelerating the speed at which innovative therapies get to benefit patients.
报告称，中国的医药创新生态系统在过去五年中已经形成，现在生态系统的首要任务之一是加快创新疗法造福患者的速度。
Astellas China Investment Co Ltd and Beijing Astellas Medical Co Ltd have been established, on the basis of the existing Astellas Pharma China Inc, to jointly promote the vigorous development of Astellas in China.
Astellas中国投资有限公司和北京Astellas医疗有限公司在现有Astellas Pharma China Inc的基础上成立，共同推动Astellas在中国的蓬勃发展。
Beijing Astellas Medical will be responsible for the sales and marketing of oncology and specialized treatment products in China, and Astellas Pharma will further focus on production and manufacturing.
北京Astellas Medical将负责肿瘤和专业治疗产品在中国的销售和营销，Astellas Pharma将进一步专注于生产和制造。
Riding on the CIIE's 'spillover effect', we hope this product can enrich effective and safe treatment options for patients," said Cecilia Qi, vice-president and general manager of pharma and vaccines for GSK China.
借助CIIE的‘溢出效应’，我们希望该产品能够丰富患者有效和安全的治疗选择，”葛兰素史克中国制药和疫苗副总裁兼总经理Cecilia Qi表示。
The companies are Biomarker Technologies Co. Ltd in Qingdao of Shandong province, Titan Scientific Co. Ltd in Shanghai, as well as Sinopharm Shanghai Medical Apparatus and Instruments Co. Ltd and Ruipu Pharma Co. Ltd in Hefei of Anhui province.
这些公司是山东青岛的生物标志物技术有限公司、上海的泰坦科学有限公司，以及安徽合肥的国药集团上海医疗器械有限公司和瑞普制药有限公司。
Suzhou-based domestic biopharmaceutical company Ascentage Pharma said ahead of International Chronic Myeloid Leukemia Day on Wednesday a new application for a drug-resistant CML treatment has been submitted in China.
在周三的国际慢性髓性白血病日之前，苏州本地的生物制药公司Ascentage Pharma表示，已在中国为一种针对药物抵抗性慢性髓性白血病的新型治疗方法提交了新药申请。
"We synthesize so many materials, and therefore our suppliers are critical," said Jerry Cacia, head of global technical development at pharma company Roche in the study.
“我们合成如此多的材料，因此供应商对我们来说至关重要，” 罗氏制药公司全球技术开发部负责人杰里·卡西亚（Jerry Cacia）在研究中表示。
Suzhou, Jiangsu province-based Ascentage Pharma is dedicated to developing first-in-class or best-in-class novel therapies with a global orientation to satisfy patients' unmet medical needs in the areas of cancer, chronic hepatitis B and age-related diseases.
总部位于江苏省苏州市的Ascentage制药公司致力于开发全球首创或同类最优的创新疗法，旨在满足癌症、慢性乙型肝炎和与年龄相关的疾病等领域的患者未竟的医疗需求。
A key drug candidate was developed for the treatment of drug-resistant chronic myeloid leukemia, which affects an estimated 10,000 patients in the country each year, said Yang Dajun, chairman and CEO of Ascentage Pharma.
Ascentage Pharma的董事长兼首席执行官杨大俊表示，一个关键的药物候选产品已被开发用于治疗耐药性慢性骨髓性白血病，该疾病每年估计影响全国约1万名患者。
"The fair is a great platform for Chinese pharmaceutical companies to showcase their products and strengths, and through forums and communication with domestic and foreign participants on the fair, we are able to promote China's innovative treatments to the outside world," said Yang Dajun, chairman and CEO of Ascentage Pharma, a Suzhou, Jiangsu province-based clinical-stage biopharmaceutical company.
“进博会为中国药企提供了展示产品和实力的绝佳平台，通过进博会上的论坛以及与国内外参会者的交流，我们得以将中国创新药推向世界。”杨大俊表示。他是江苏苏州一家临床阶段生物制药公司——亚盛医药的董事长兼首席执行官。
Jasmine Cui, co-founder, chairwoman and CEO of Beijing-based InnoCare Pharma Ltd, said: "As a player in China's booming biopharmaceutical industry, we are very excited to see the industry's progress in innovation and development, as well as to demonstrate innovations and achievements of our own company through the fair.
北京诺诚健华医药科技有限公司联合创始人、董事长兼首席执行官崔霁松表示：“作为中国蓬勃发展的生物医药行业的一员，我们非常欣喜地见证了行业在创新和发展方面的进步，同时也期待通过此次展会展示我们公司自身的创新成果和成就。”
The high-speed growth of innovative Chinese biopharmaceutical companies -- after more than a decade of progress in terms of new drug development, conducting clinical trials, and the talent reservoir -- may last for years, said Yang Dajun, chairman and CEO of Ascentage Pharma, a Suzhou-based biopharmaceutical company.
苏州亚盛药业有限公司（Ascentage Pharma）董事长兼首席执行官杨大俊表示，在新药研发、临床试验开展和人才库建设方面经过十多年的发展之后，中国创新生物制药公司的高速增长可能会持续多年。
US-based Biogen Inc and Hong Kong-listed Chinese mainland biopharma startup InnoCare Pharma Ltd announced on Monday that they have entered into a license and collaboration agreement for orelabrutinib, a drug candidate currently in a multi-country, placebo-controlled Phase 2 trial for the potential treatment of multiple sclerosis, a rare disease of the nervous system characterized by loss of feeling and control of movement and speech.
美国生物技术公司Biogen Inc和在香港上市的中国内地生物制药初创公司InnoCare Pharma Ltd于周一宣布，双方已就orelabrutinib达成许可和合作协议。Orelabrutinib是一种药物候选物，目前正在进行跨国、安慰剂对照的二期临床试验，用于治疗多发性硬化症(MS)这一罕见的神经系统疾病，该疾病以感觉丧失、运动和言语控制能力下降为特征。
"We are glad to see that this vaccine, jointly developed by Fosun and BioNTech, can play a positive role in the prevention and control of the epidemic in Taiwan," said Wu Yifang, chairman and CEO of Fosun Pharma.
“我们高兴地看到，复星医药和BioNTech共同开发的这款疫苗，能够在台湾地区的疫情防控中发挥积极作用。”复星医药董事长兼首席执行官吴以芳表示。
Zhu Jianwei, dean of the School of Medicine at Shanghai Jiao Tong University, said that in recent years, with increasing recognition from the international community and the enhancement of the country's policy support, China's biopharmaceutical market has been growing rapidly, with the compound annual growth rate of the sector higher than that of China's overall pharma industry, and there have been many breakthroughs in the sector.
上海交通大学医学院院长朱健伟表示，近年来，随着国际社会的认可度不断提高和国家政策扶持力度的增强，中国生物医药市场正快速增长，该行业的复合年增长率高于中国整个制药行业，且该领域出现了许多突破。
Xospata, orgilteritinib fumarate tablets, an innovative cancer treatment produced by multinational pharmaceutical Astellas Pharma, was officially prescribed to Chinese patients on Friday, thanks to the distribution network and commercialization platform of Qingdao Baheal Medical.
日本跨国制药公司Astellas Pharma生产的创新癌症治疗药物Xospata（奥西替尼富马酸片）于上周五通过青岛百禾医疗的分销网络和商业化平台正式在中国患者中启用。
At the beginning of last year, BeiGene worked with United Kingdom-based biopharmaceutical company EUSA Pharma to introduce a monoclonal antibody drug for neuroblastoma for Chinese patients.
去年年初， BeiGene与英国生物制药公司EUSA Pharma合作，为中国患者引进了一种针对神经母细胞瘤的单克隆抗体药物。
Surging export orders show China's pharma products are trusted overseasAt Sinovac Biotech Ltd's base in Daxing district of Beijing, employees are busy manufacturing CoronaVac, the inactivated COVID-19 vaccine, in bulk.
在北京市大兴区科兴中维生物技术有限公司基地，工人们正忙着大批量生产CoronaVac灭活新冠疫苗。这家公司的出口订单激增，显示出中国医药产品在海外受到信赖。
Shanghai Yingli Pharmaceutical Co Ltd (Yingli Pharma), a small-molecule innovation drug research and development company, formed a new partnership with Jiangsu Hengrui Medicine Co Ltd (Hengrui Medicine) on Monday to accelerate the expansion of its oncology business in China, the second-largest pharmaceutical market in the world, the company said in a statement.
上海亿帆医药有限公司（亿帆医药），一家小分子创新药物研发公司，周一宣布与江苏恒瑞医药股份有限公司（恒瑞医药）建立新的合作伙伴关系，以加速其在中国——这个世界第二大药品市场的肿瘤业务扩张，该公司在一份声明中表示。
As part of the cooperation, the Jiangsu province-based group will invest $20 million in Yingli Pharma as an equity investment.
作为合作的一部分，总部位于江苏的该集团将向 Yingli Pharma 投资 2000 万美元作为股权投资。
"The strategic collaboration with Hengrui Medicine is a milestone that will enable Yingli Pharma to further promote the commercialization of developed innovative drugs," said Xu Zusheng, Yingli co-founder.
“与恒瑞医药的战略合作是一个里程碑，这将使亿帆医药能够进一步推动开发的创新药物的商业化，”亿帆医药联合创始人徐祝生表示。
"It also demonstrates the confidence mature industrial investors have in our product pipeline and innovation, and fully recognizes the strategic vision of Yingli Pharma to build an international biopharmaceutical company," he said.
这同时也显示了成熟产业投资者对我们产品管线和创新的信心，充分认可了亿珂医药打造国际生物制药公司的战略视野。”
Established in 2011, Yingli Pharma focuses on the development and commercialization of innovative small-molecule drugs for hematological tumors, solid tumors and kidney-related metabolic diseases.
英利医药成立于2011年，专注于开发和商业化针对血液肿瘤、实体瘤和肾相关代谢疾病的创新小分子药物。
Switzerland-based pharmaceutical company Novartis Pharma AG expects to double its sales in China and submit 50 new drug applications in the country by 2024, it announced in its annual financial report released on Tuesday.
瑞士制药巨头诺华制药(Novartis Pharma AG)周二发布的年报显示，该公司预计到2024年在中国的销售额将翻一番，并在中国提交50种新药申请。
InnoCare Pharma Limited, a Hong Kong-listed Chinese biopharma startup, officially launched its cancer therapy orelabrutinib in Beijing on Tuesday, marking its first commercial product since it was founded in 2015.
香港上市的中国生物制药初创公司英科瑞霖有限公司(InnoCare Pharma Limited)周二在北京正式推出其抗癌疗法奥雷巴替尼，这是该公司自2015年成立以来的首款商业化产品。
Famous biology Shi Yigong is the co-founder and president of the Science Advisory Board of InnoCare Pharma.
著名生物学家施一公是InnoCare Pharma科学顾问委员会的联合创始人和主席。
On March 13, Fosun Pharma became the strategic partner of BioNTech in China, jointly developing and commercializing vaccine products for COVID-19 based on its proprietary mRNA technology platform in China.
3月13日，复星医药成为BioNTech在中国的战略合作伙伴，双方将基于BioNTech的专有mRNA技术平台，在中国共同开发和商业化针对COVID-19的疫苗产品。
Apart from discussing the research and development plans with partners and completing clinical trials in China, Fosun Pharma has also designed and completed animal challenge trials of selected mRNA vaccines, including BNT162b2, in collaboration with Chinese research institutes, and shared outcomes with partners in a timely manner.
除了与合作伙伴讨论研发计划并在中国进行临床试验外，复星医药还与中国研究机构合作，设计并完成了选定的mRNA疫苗（包括BNT162b2）的动物挑战试验，并及时与合作伙伴分享了试验结果。
Hui Aimin, chief medical officer of Fosun Pharma, said that the COVID-19 pandemic proves once again that global cooperation is needed to control infectious diseases.
复星医药首席医学官余民表示，新冠疫情再次证明，在控制传染病方面需要开展全球合作。
Fosun Pharma announced on Wednesday a private placement plan in the A-share market.
复星医药周三宣布了在A股市场进行定向增发的计划。
Our global products that were showcased at last year's CIIE have all been well-received since their launch in China," said Qi Xin, vice-president and general manager of pharma and vaccines at GSK China.
“去年进博会我们展示的全球产品自在中国上市以来，都受到了很好的反响，”葛兰素史克中国医药保健总经理兼副总裁齐欣表示。
The new establishment, Novo Nordisk (Shanghai) Pharma Trading Co Ltd, which entails an investment totaling 200 million yuan ($30 million), will focus on research and development, import and distribution of finished products.
这家名为诺和诺德(上海)医药贸易有限公司的新企业投资额达2亿元人民币(合3,000万美元)，将专注于研发、进口和分销成品药。
Hong Chow, CEO of Roche Pharma China, said during the third China International Import Expo that the company has prioritized R&D input in China as a core pillar of Roche's 2030 strategy.
罗氏制药中国区首席执行官洪小文在第三届中国国际进口博览会上表示，公司已将在中国的研发投入作为罗氏2030战略的核心支柱。
Zang, I-Mab's founder and honorary chairman, said the collaboration comes at a critical time, recognizes the R&D capabilities of the company, and will boost its collaboration with Big Pharma at home and abroad, to accelerate its global presence in new drug development and commercialization.
Schott, a producer of specialty glass and supplier of pharma packaging to Novo Nordisk, has committed to becoming carbon neutral by 2030.
What's more exciting is that the highly fragmented market, which covers everything from medicines to drug products manufactured with living organisms, is filled with a legion of smaller firms hoping to take on global pharma giants.
This contrasts with the more common choice of Shanghai, where global pharma giants locate their China, Asia-Pacific, or even global headquarters of certain business units.
- Chinese pharmaceutical company Fosun Pharma on Tuesday donated anti-malaria drugs to Kenya's health ministry to boost the war against the tropical disease that is the leading cause of death among pregnant women and children below five years in the country.
As a window to show China's deepening reform and opening-up to the world, the import expo provides an excellent platform and opportunity to enterprises, and links enterprises with governments and each other, said Hong Chow, general manager of Roche Pharma China, adding the company will reinforce long-term cooperation with the expo and bring more innovative products and solutions to Chinese customers.
Yiling Pharma's products get overseas health bodies' nods for market accessAs the COVID-19 epidemic situation worsened overseas, Koh Chok Tong, a 35-year-old engineer in Singapore, felt he was lucky enough to be able to buy Lianhuaqingwen capsules manufactured by Shijiazhuang, Hebei province-based Chinese drug firm Yiling Pharmaceutical at a local pharmacy.
Yiling Pharma makes the herbal compound using the traditional Chinese medicine, or TCM, system.
Yiling Pharma announced in May its Lianhuaqingwen capsules had been officially listed as Chinese proprietary medicine to treat influenza by the Healthy Sciences Authority of Singapore, which meant the Chinese medicine has been granted local market access.
Wu Rui, board director and secretary of the board of Yiling Pharma, said the international journey of Lianhuaqingwen capsules started years ago.
Yiling Pharma said it will continue to explore the innovative development path of TCM internationalization.
The trial came about after Oklahoma had resolved claims against OxyContin maker Purdue Pharma LP in March for $270 million and against Teva in May for $85 million, leaving J&J as the lone defendant.
Shanghai Pharma Engine Co Ltd has jointly built the facility with Johnson & Johnson.
It was co-built by the company and Shanghai Pharma Engine Co. Ltd. Paul Stoffels, vice chairman of Johnson & Johnson's executive committee, said the Shanghai incubator would connect local and global entrepreneurs to help transform ideas into breakthrough health solutions.
It has been independently developed by Fosun Orinove, a subsidiary of Fosun Pharma.
As of last month, Fosun Pharma had invested 45.47 million yuan ($6.57 million) in the drug.
In recent years, Fosun Pharma has expanded investment on innovation and oncology research, and worked on small molecular innovative drugs, biologics and cellular immunotherapy.
The drug was developed by Henlius, Fosun Pharma's biologics platform,Faced with unmet medical needs, Fosun Pharma is also introducing a number of advanced, cutting-edge products and technologies through corporate cooperation.
We are actually just signing with the Chinese company Luye Pharma Group for a mild step in a drug that we will be promoting.
ReNeuron, a British biotechnology company that develops stem cell treatments for brain and eye conditions, has sold the Chinese rights for two of its therapies to pharmaceutical giant Fosun Pharma in a deal worth 80 million pounds ($105 million).
The deal means Fosun Pharma will fully fund the future development of ReNeuron’s stroke and retina treatments in China, including clinical trials and commercialization activities, according to Olav Hellebo, ReNeuron’s chief executive.
“China represents a significant market opportunity for our products and we look forward to working with Fosun Pharma to ultimately bring these treatments to the many patients in China who may benefit from them,” Hellebo said.